Glaxosmithkline is extending its product portfolio in the Middle East. The company has acquired the branded generics business of Bristol-Myers Squibb in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2 million.
Related Articles :
Keywords : Glaxosmithkline
Reader comments (0)